Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC

Heather Wakelee, MD
Published: Wednesday, Dec 07, 2016



Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Wakelee discusses a study in which the researchers investigated whether a mutation enrichment next-generation sequencing could improve mutation detection in plasma and urine from the TIGER-X trial, which was a phase 1/2 study of rociletinib in patients with EGFR mutation-positive advanced NSCLC.

Of 174 matched tissue, plasma and urine specimens, 145 (83.3%) were found to be positive for the T790M mutation by central tissue testing, 142 (81.6%) of which were positive by plasma, and 139 (79.9%) positive by urine. Urine and plasma combined identified 165 cases (94.8%) as T790M-positive.

This combination of urine and plasma testing may be considered before tissue testing in EGFR TKI resistant NSCLC, including patients without extrathoracic metastases.

<<< View more from the IASLC 17th World Conference on Lung Cancer



Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Wakelee discusses a study in which the researchers investigated whether a mutation enrichment next-generation sequencing could improve mutation detection in plasma and urine from the TIGER-X trial, which was a phase 1/2 study of rociletinib in patients with EGFR mutation-positive advanced NSCLC.

Of 174 matched tissue, plasma and urine specimens, 145 (83.3%) were found to be positive for the T790M mutation by central tissue testing, 142 (81.6%) of which were positive by plasma, and 139 (79.9%) positive by urine. Urine and plasma combined identified 165 cases (94.8%) as T790M-positive.

This combination of urine and plasma testing may be considered before tissue testing in EGFR TKI resistant NSCLC, including patients without extrathoracic metastases.

<<< View more from the IASLC 17th World Conference on Lung Cancer


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x